Literature DB >> 2895455

Clinically important adverse effects and drug interactions with H2-receptor antagonists: an update.

M J Sax1.   

Abstract

The H2-receptor antagonists cimetidine, ranitidine, and famotidine are well tolerated, with a low frequency and similar spectrum of adverse effects. The occasional problematic effects that have been associated with these agents include central nervous system symptoms (mental confusion, headache, and depression), rare cases of thrombocytopenia, and cardiovascular events related to the rate of intravenous infusion. Severe renal and hepatic impairment appear to be associated with a higher occurrence of central nervous system effects. Because the H2-receptor antagonists elevate gastric pH, bind to and inhibit the hepatic cytochrome P-450 enzyme system, and undergo renal tubular secretion, competition with other drugs sharing these pathways has resulted in a number of drug interactions, most of which are not clinically significant. The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring. Recent data suggest that administering cimetidine 800 mg at bedtime has less effect on the serum concentrations of warfarin and theophylline than other dosing regimens. Evidence to date indicates that famotidine does not bind to cytochrome P-450 to a significant extent, and interactions with drugs metabolized by this system have not been reported; however, clinical experience with this agent is very limited.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2895455     DOI: 10.1002/j.1875-9114.1987.tb03534.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

Review 1.  Safety of acid-suppressing drugs.

Authors:  R A Smallwood; R G Berlin; N Castagnoli; H P Festen; C J Hawkey; S K Lam; M J Langman; P Lundborg; A Parkinson
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 2.  Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole.

Authors:  T J Humphries
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

3.  Depression and anxiety disorders among gastroenterologic outpatients.

Authors:  Ilker Tasci; Umut Safer
Journal:  Saudi J Gastroenterol       Date:  2014 Sep-Oct       Impact factor: 2.485

4.  A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.

Authors:  Divya Patel; Richard Bertz; Song Ren; David W Boulton; Mats Någård
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

5.  Sonchus oleraceus L. Promotes Gastroprotection in Rodents via Antioxidant, Anti-Inflammatory, and Antisecretory Activities.

Authors:  Cristian A D Vecchia; Gelvani Locateli; Patricia Z Serpa; Denise Bianchin Gomes; Jackeline Ernetti; Daniela Miorando; Maria Eduarda D C Zanatta; Ruan Kaio Silva Nunes; Silvana M Wildner; Max V Gutiérrez; Wagner Vilegas; Lincon B Somensi; Luisa M Silva; Walter A Roman Junior
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-23       Impact factor: 2.650

6.  Protective effect of Rhei Rhizoma on reflux esophagitis in rats via Nrf2-mediated inhibition of NF-κB signaling pathway.

Authors:  O Jun Kwon; Byung Kil Choo; Joo Young Lee; Min Yeong Kim; Sung Ho Shin; Bu-Il Seo; Young-Bae Seo; Man Hee Rhee; Mi-Rae Shin; Gyo-Nam Kim; Chan Hum Park; Seong-Soo Roh
Journal:  BMC Complement Altern Med       Date:  2016-01-09       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.